Novo Nordisk (NVO.N) stated that in clinical trials, the company's cangrisema failed to meet the efficacy criteria of being non-inferior to Eli Lilly's tirzepatide.

2026-02-23

Novo Nordisk (NVO.N) stated that in clinical trials, the company's cangrisema failed to meet the efficacy criteria of being non-inferior to Eli Lilly's tirzepatide.

Other News
2026-02-23

Market news: India is studying the impact of the U.S. Supreme Court's decision to overturn Trump's tariffs on its bilateral trade agreement with the United States.

2026-02-23

[ECB President Christine Lagarde Receives Compensation from BIS, Accused of Double Standards by Employees] Despite the European Central Bank's (ECB) ban on employees accepting payments from third parties, ECB President Christine Lagarde, as a member